Integra LifeSciences Announces Agreement with Vomaris Wound Care, Inc. to Commercialize VolTAC™ Antimicrobial Wound Dressing

PLAINSBORO, N.J., April 14, 2016 -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that its subsidiary, Integra LifeSciences Corporation, has entered into an agreement with Vomaris Wound Care, Inc., a company specializing in microcurrent solutions for the advanced wound care market. Vomaris’s Advanced Microcurrent Technology® (AMT) platform recently earned Frost & Sullivan’s 2016 Best Practices Award for New Product Innovation for pioneering technology that utilizes electrical energy for wound management.

AMT powers a new generation of antimicrobial wound dressing solutions for wound and incisional care. Containing embedded microcell batteries, comprising elemental silver and zinc, the dressing generates microcurrents at the dressing surface in the presence of moisture, to minimize or prevent the growth of microorganisms within the dressing.  

Under the agreement, Integra has exclusive rights, subject to a limited number of specified exceptions, to market and sell Vomaris’s AMT technology to manage chronic and acute wounds, including burns and surgical incisional wounds.  Integra’s new product line, marketed under the name Integra® VolTAC™, will offer two product groups – a Single Layer Dressing and Composite Adhesive Dressing, both indicated for the management of partial and full thickness wounds such as pressure, venous and diabetic ulcers, first and second degree burns, surgical incisions and/or graft recipient sites. Integra intends to market and sell this exciting new product through its wound care, surgical, and reconstructive sales channels.  These channels target hospitals, ambulatory surgery centers, wound care clinics, and physicians’ offices.

“VolTAC has been shown to completely kill a broad spectrum of microbes, including several multidrug-resistant strains of wound pathogens such as S. aureus (MRSA), K. pneumonia (ESBL), and P. aeruginosa (MDR), within 24 hours of exposure to VolTAC¹.  VolTAC gives us a novel advanced wound care technology that can be used to manage chronic and acute wounds treated in the operating room and in the wound care clinic.  This technology complements our Omnigraft™ technology by providing surgeons treatment options for all Diabetic Foot Ulcers (DFUs),” said Mark Augusti, President of Integra’s Orthopedics and Tissue Technologies business.

“Vomaris is proud to be partnering with Integra. With their strong presence and expertise in wound care, we are confident they will dramatically expand the use of AMT, helping clinicians address the many challenges associated with wound healing,” said Mike Nagel, President and Chief Executive Officer of Vomaris Innovations, Inc. 

About Integra
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com.

About Vomaris
Vomaris Wound Care, Inc. is a privately held company specializing in electroceutical solutions for the wound care market and beyond.  Vomaris’ core technology platform, Procellera® with Advanced Microcurrent Technology® (AMT) is used in multiple acute and chronic wound care settings, including clinical, animal and consumer health. It is currently sold in the United States through strategic distribution partners and plans are underway for global expansion.  Learn more at http://www.Procellera.com.

References
1. Kim H et al. Antibacterial Efficacy Testing of a Bioelectric Wound Dressing Against Clinical Wound Pathogens. The Open Microbiology Journal 2014; 8:15-21.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2015 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Company

Investors
Angela Steinway                                    
609-936-2268                                                       
[email protected]

Michael Beaulieu
609-750-2827
[email protected]

Media
Gianna Sabella
609-775-8553
[email protected]